Owlstone Medical (“Owlstone”), the world leader in breathing biopsy® For applications in early disease detection and medical detection and accuracy, it announced today that the Cystic Union Foundation has investing $ 2.3 million (about $ 1.7 million) in Owlstone to develop a breathing test for breathing for Pseudomonas aeruginosa (PA) Detection in patients with cystic fibrosis (CF).
The purpose of the investment is to develop a breathing test suitable both for early detection of the new PA infection and for the monitoring of chronic infection in patients with CF, with diagnostic precision at least comparable to sputum cultivation tests. Utilizing Owlstone’s know -how in the analysis of volatile organic union (VOC), the test will also develop to distinguish RA from S. Aureus and other common respiratory bacterial pathogens found in the lungs of people with CF.
Initial work will focus on Chronic PA to create scientific proof of the principle that WTOs in breathing can detect this lung infection and be used as part of long -term monitoring of infection. If it is successful, additional work can be organized to test the ability of this approach to detect new PA infections – an important event in clinical care of people with c.
CF is a progressive genetic disorder that affects over 105,000 people worldwide. It is characterized by excessive production of mucus that traps pathogens in the lungs, CF causes severe lung infections and can lead to respiratory failure. PA, which affects about 25% of patients with CF, is a significant threat to people with See once it is installed in the lungs, PA is very difficult to eliminate, making early detection and aggressive treatment of critical infection.
PA is usually detected through sputum cultivation. However, this is difficult to perform in many children and becomes increasingly difficult for adults with CF due to the beneficial effects of other treatments that reduce the mucus of the airways and therefore the ability to provide an appropriate sample of sputum.
Owlstone’s experience in detecting Owlstone’s infectious disease through works with the US Department of Defense, the Gates Foundation and other partners supported by the Breath biopsy platform, places Owlstone in a great position to help improve the effects for patients with CF who have contaminated CF patients Pseudomonas aeruginosa. ”
Billy Boyle, co -founder and CEO, Owlstone Medical
Added: “The data from the study will also be introduced to Owlstone’s Atlas Breath Voc, where they will continue to be used in clinical studies and analyzes to support further biomarker and development test in a wide range of diseases. “
